Merck submits Erbitux indication extension to EMA for NSCLC treatment

[News]

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

More... (http://www.news-medical.net/news/20110330/Merck-submits-Erbitux-indication-extension-to-EMA-for-NSCLC-treatment.aspx)